An Analysis of Nectin-4 (PVRL4) in Penile Squamous Cell Carcinoma

Thomas, 2021, Penile cancer, Nat Rev Dis Primers, 7, 11, 10.1038/s41572-021-00246-5 Joshi, 2022, Immune-based therapies in penile cancer, Nat Rev Urol, 19, 457, 10.1038/s41585-022-00617-x Joshi, 2022, Penile cancer: updates in systemic therapy, Asian J Urol, 9, 374, 10.1016/j.ajur.2022.03.006 Yan, 2022, First-line programmed death receptor-1 (PD-1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum-based chemotherapy, for stage IV penile cancer, BJU Int Liu, 2021, Role of Nectin-4 protein in cancer, Int J Oncol, 59, 93, 10.3892/ijo.2021.5273 Reches, 2020, Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity, J Immunother Cancer, 8, e000266, 10.1136/jitc-2019-000266 Heath, 2021, The biology and rationale of targeting nectin-4 in urothelial carcinoma, Nat Rev Urol, 18, 93, 10.1038/s41585-020-00394-5 Yuan, 2019, Intrinsic radiosensitivity, genomic-based radiation dose and patterns of failure of penile cancer in response to adjuvant radiation therapy, Rep Pract Oncol Radiother, 24, 593, 10.1016/j.rpor.2019.09.006 Kuasne, 2015, Genome-wide methylation and transcriptome analysis in penile carcinoma: uncovering new molecular markers, Clin Epigenet, 7, 46, 10.1186/s13148-015-0082-4 Azizi, 2019, Impact of PI3K-AKT-mTOR signaling pathway up-regulation on prognosis of penile squamous-cell carcinoma: results from a tissue microarray study and review of the literature, Clin Genitourin Cancer, 17, e80, 10.1016/j.clgc.2018.09.012